Leukemia
This journal publishes high quality, peer reviewed research that covers all aspects of the research and treatment of leukemia and allied diseases. Topics of interest include oncogenes, growth factors, stem cells, leukemia genomics, cell cycle, signal transduction and molecular targets for therapy.
VEXAS Syndrome: Hope, Challenges, Solutions, and the Road Ahead
This post aims to raise awareness, build understanding, and inspire action within the medical and patient communities alike. The road is long, but with continued collaboration and innovation, we can offer new hope to those affected by VEXAS syndrome.
Mutation in Bruton Tyrosine Kinase (BTK) A428D Confers Resistance To BTK-Degrader Therapy In Chronic Lymphocytic Leukemia
Drugs that target BTK for proteasomal degradation, so-call BTK degraders, are presumed able to mitigate the risk of drug resistance due to BTK mutations. In Leukemia 38:1818 (2024), Kipps and colleagues describe a patient who developed resistance to the BTK-degrader BGB-16673 via a mutation in BTK.
Redefining high risk multiple myeloma with an APOBEC/Inflammation-based classifier.
Multiple myeloma (MM), a malignancy of plasma cells in the bone marrow, remains a significant clinical challenge due to its diverse presentation and progression.
A call for individual risk stratification on early morbidity and mortality in patients with newly diagnosed multiple myeloma
Behind the paper of „Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients” - an international team effort from the HOVON, EMN and GMMG study groups.
